Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin

MECHELEN, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) —

Galapagos  NV (Euronext:  GLPG) announced
today that the Company will present in vitro and Phase 1 data showing potent and
selective inhibition of FFA2 by GLPG0974 at the United European Gastroenterology
Week,  taking place  from 12 to  16 October 2013 in  Berlin, Germany.  "The FFA2
antagonist  GLPG0974: Opportunity to  treat neutrophil-driven inflammation" will
be  presented on 16 October from 9 am to 2 pm CET and has been granted Poster of
Excellence  designation from the  UEG Week Scientific  Committee.  The poster is
also now available online at

FFA2  (free fatty acid receptor  2) has been shown to  play a role in neutrophil
migration.   Over-activity  of  neutrophils  is  a  cause  of  tissue  damage in
illnesses such as inflammatory bowel disease.  In the EUG Week poster, Galapagos
provides  in  vitro  pharmacology  supporting  that  GLPG0974  is  a  potent and
selective   antagonist   of   FFA2,   and  favorable  Phase  I  pharmacokinetic,
pharmacodynamic, and safety data with GLPG0974.

About candidate drug GLPG0974
GLPG0974 is an orally available small molecule that reduces migration of
neutrophils, one of the critical cell types in inflammatory processes, by potent
inhibition of FFA2 (also known as GPR43). Over-activity of neutrophils is a
cause of tissue damage in illnesses such as inflammatory bowel disease.  A
reduction of neutrophil activation and migration by inhibition of FFA2 may
provide for a novel anti-inflammatory treatment approach.  By inhibiting FFA2,
GLPG0974 prevents free fatty acid-induced activation and migration of
neutrophils towards an inflammatory site, such as in the gut of patients with
inflammatory bowel disease.  GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically.  Galapagos expects to report results of the Proof of
Concept study in ulcerative colitis in early 2014.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie  and Galapagos signed an agreement  in CF where they work collaboratively
to  develop and commercialize oral drugs that  address two mutations in the CFTR
gene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie and
Galapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  be
responsible  for  further  development  and  commercialization of GLPG0634 after
Phase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment  of rheumatoid arthritis and  potentially other inflammatory diseases,
currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies in
Crohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 in
lupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   by
GlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to be
evaluated  clinically for the treatment  of IBD; this program  is currently in a
Proof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule that
targets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has around  800 employees and  operates facilities  in five countries,
with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:


Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Galapagos to present Phase 1 data on GLPG0974: